Journal Article
. 2016 Jun; 3(1):e1048929.
doi: 10.1080/23723556.2015.1048929.

Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma

Matthew Hellmann 1 Naiyer Rizvi 2 Jedd D Wolchok 1 Timothy A Chan 3 
  • PMID: 27308563
  •     10 References
  •     18 citations


The recent successes of immune checkpoint therapies have established a new era for the treatment of patients with cancer, yet the predictors of response remain largely undetermined. We recently demonstrated that the genomic landscape of lung cancers substantially influences the response to programmed cell death 1 receptor (PD-1) blockade, providing new insights into the molecular determinants of the response to immunotherapy.

Keywords: Cancer; immunotherapy; lung; mutation.

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
Claire Palles, Jean-Baptiste Cazier, +37 authors, Ian Tomlinson.
Nat Genet, 2012 Dec 25; 45(2). PMID: 23263490    Free PMC article.
Highly Cited.
Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, +61 authors, Gad Getz.
Nature, 2013 Jun 19; 499(7457). PMID: 23770567    Free PMC article.
Highly Cited.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network.
Nature, 2014 Aug 01; 511(7511). PMID: 25079552    Free PMC article.
Highly Cited.
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.
Gerd P Pfeifer, Mikhail F Denissenko, +3 authors, Pierre Hainaut.
Oncogene, 2002 Oct 16; 21(48). PMID: 12379884
Highly Cited. Review.
Cancer genome landscapes.
Bert Vogelstein, Nickolas Papadopoulos, +3 authors, Kenneth W Kinzler.
Science, 2013 Mar 30; 339(6127). PMID: 23539594    Free PMC article.
Highly Cited. Review.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
Ramaswamy Govindan, Li Ding, +18 authors, Richard K Wilson.
Cell, 2012 Sep 18; 150(6). PMID: 22980976    Free PMC article.
Highly Cited.
Comprehensive genomic characterization of squamous cell lung cancers.
Cancer Genome Atlas Research Network.
Nature, 2012 Sep 11; 489(7417). PMID: 22960745    Free PMC article.
Highly Cited.
Molecular chess? Hallmarks of anti-cancer drug resistance.
Ian A Cree, Peter Charlton.
BMC Cancer, 2017 Jan 07; 17(1). PMID: 28056859    Free PMC article.
Highly Cited. Review.
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim.
Oncotarget, 2017 May 20; 8(29). PMID: 28525386    Free PMC article.
Atezolizumab for the treatment of non-small cell lung cancer.
Fernando C Santini, Charles M Rudin.
Expert Rev Clin Pharmacol, 2017 Jul 18; 10(9). PMID: 28714780    Free PMC article.
PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.
Urska Janzic, Izidor Kern, +2 authors, Tanja Cufer.
Radiol Oncol, 2017 Sep 30; 51(3). PMID: 28959173    Free PMC article.
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190984    Free PMC article.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.
Elizabeth A Comen, Robert L Bowman, Maria Kleppe.
Front Cell Dev Biol, 2018 Jun 28; 6. PMID: 29946544    Free PMC article.
Immune checkpoint inhibitors and small cell lung cancer: what's new?
Sabine Schmid, Martin Früh.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29953115    Free PMC article.
DNA repair defects and implications for immunotherapy.
Katherine M Bever, Dung T Le.
J Clin Invest, 2018 Oct 03; 128(10). PMID: 30272580    Free PMC article.
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?
Matthew Evans, Brendan O'Sullivan, Matthew Smith, Philippe Taniere.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505713    Free PMC article.
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.
Hirokazu Tokuyasu, Mika Horie, +3 authors, Akira Yamasaki.
Respir Med Case Rep, 2019 Dec 31; 29. PMID: 31886125    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Wenbin Li, Peng Song, +4 authors, Shugeng Gao.
Thorac Cancer, 2018 Dec 12; 10(2). PMID: 30536734    Free PMC article.
CNOT4 enhances the efficacy of anti-PD-1 immunotherapy in a model of non-small cell lung cancer.
Biao Zhang, Song Han, Haitao Ma, Shaomu Chen.
FEBS Open Bio, 2020 Oct 10; 10(12). PMID: 33034149    Free PMC article.
Chemo-immunotherapy as first-line treatment for small-cell lung cancer.
Saira Farid, Stephen V Liu.
Ther Adv Med Oncol, 2021 Jan 09; 12. PMID: 33414848    Free PMC article.
Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Fan Shi, Jin Su, +2 authors, Tao Wang.
Mol Cell Biochem, 2020 Nov 04; 476(2). PMID: 33141310
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab.
Ou Yamaguchi, Kyoichi Kaira, +8 authors, Hiroshi Kagamu.
Thorac Cancer, 2020 Nov 14; 12(3). PMID: 33185333    Free PMC article.
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.
Ashwin Somasundaram, Mark A Socinski, Liza C Villaruz.
Drugs, 2020 May 22; 80(9). PMID: 32436070    Free PMC article.